With new FDA nod in ulcerative colitis, J&J's Tremfya becomes 1st IL-23 med with IV and subQ options across IBD treatment
22nd September 2025 Uncategorised 0The FDA has approved a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis (UC). The green light builds on Tremfya’s initial nod in UC and a Crohn’s disease approval in March, making the medicine the first IL-23 inhibitor to offer both under-the-skin injection and IV dosing options from the beginning of treatment through maintenance therapy for IBD patients.
More: With new FDA nod in ulcerative colitis, J&J's Tremfya becomes 1st IL-23 med with IV and subQ options across IBD treatment
Source: fierce